Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 91INDUSTRY 11NIH 10NETWORK 4UNKNOWN 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Capecitabine 15Paclitaxel 13S 1 (combination) 9apatinib 8Oxaliplatin 8Carboplatin 8Cisplatin 7pyrotinib 6Epirubicin 6Docetaxel 6sintilimab 5camrelizumab 5anlotinib 5Radiotherapy 5Drug Therapy 5130-nm albumin-bound paclitaxel 5nimotuzumab 4nedaplatin 4Vinorelbine 4Temozolomide 4Irinotecan 4Fulvestrant 4Etoposide 4Bevacizumab 4toripalimab 3titanium silicide 3exemestane 3Trastuzumab 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × UNKNOWN × Rituximab × Clear all
NCT04994626 2021-08-06

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

ChineseAMS

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Recurrence

NCT04425824 2020-06-16

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

ChineseAMS

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡